Dr. Bekaii-Saab on Microsatellite Instability in Colorectal Cancer

Tanios Bekaii-Saab, MD
Published: Friday, Sep 16, 2016



Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses microsatellite instability (MSI) in colorectal cancer.

The MSI group makes up about 4% of all patients with stage IV cancer. For those patients, studies suggest that using immunotherapies such as PD-1 inhibitors tend to induce significant responses that are both deep and durable, says Bekaii-Saab.

The question, though, is whether these PD-1 inhibitors would produce better outcomes than chemotherapy, or would add any benefit to chemotherapy in combination. If the research suggests that PD-1 inhibitors hold promising results in randomized trials in the first line, then it is likely that they will replace chemotherapy for MSI patients.


Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses microsatellite instability (MSI) in colorectal cancer.

The MSI group makes up about 4% of all patients with stage IV cancer. For those patients, studies suggest that using immunotherapies such as PD-1 inhibitors tend to induce significant responses that are both deep and durable, says Bekaii-Saab.

The question, though, is whether these PD-1 inhibitors would produce better outcomes than chemotherapy, or would add any benefit to chemotherapy in combination. If the research suggests that PD-1 inhibitors hold promising results in randomized trials in the first line, then it is likely that they will replace chemotherapy for MSI patients.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x